The US Food and Drug Administration needs to take a more proactive approach to communicating to counter the tide of misinformation consumers are exposed to, a new report commissioned by the agency instructs. However, FDA Commissioner Robert Califf and other experts cautioned that some of this work may need to be led by outside parties to ensure public buy in.
Prebunk: FDA Needs To Get Ahead Of Misinformation, But It Likely Can’t Drive The Effort
New report offers a five-point plan for FDA to improve the public’s understanding of its role including pushing the agency to be more proactive in listening for, spotting, and addressing misconceptions before they escalate. But experts caution that this must be done carefully, or it could fuel more distrust.
More from Agency Leadership
• By
In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."
• By
A former CMS manager worries casework and other necessary functions could suffer as a result of the 300 staff cuts at the agency that are part of a massive HHS restructuring.
• By
The April departures of Paul Kluetz and Marc Theoret follow resignations by other senior agency scientific staff and come on top of HHS’ plans to lay off 3,500 FDA employees.
• By
About 3,500 full-time FDA employees are expected to be laid off as part of a restructuring of the Health and Human Services Department and experts questioned whether the cuts could be implemented without harming FDA’s core mission.
More from Pink Sheet
• By
Pink Sheet reporter and editors discuss how staff may not be the only thing the FDA could lose with the latest layoffs announced by the Health and Human Services Department.
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
• By
Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.